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Inhibitory receptors control immune responses prevent-
ing exacerbated T cell activation and the onset of autoim-
munity; however, they also limit antitumor immunity.
Enhanced co-expression of PD1 and LAG3 phenotypi-
cally mark functionally exhausted tumor-specific T cells,
with dual PD1/LAG3 blockade synergistically limiting
tumor growth in murine models. Like PD1, LAG3
expression is induced on activated T cells to negatively
regulate T cell activation and proliferation and LAG3 is
also required for maximal regulatory T (Treg) cell func-
tion. However, LAG3 expression and function is itself
regulated by cell surface cleavage of the transmembrane
domain connecting peptide by ADAM10 and ADAM17
metalloproteinase-disintegrins. This releases soluble
LAG3, of which no biological function has been found to
date. To investigate the impact of LAG3 cleavage on T
cells within tumors, a non-cleavable LAG3 mouse
(LAG3.NC) was generated in which exons 7 and 8
of Lag3, including the connecting peptide, is deleted in
Cre-expressing cells. These exons are replaced and modi-
fied so that the connecting peptide is absent preventing
LAG3 cleavage. LAG3.NC CD4Cre mice (with non-
cleavable LAG3 expressed on all CD8+ and CD4+ T cells,
including Tregs) and LAG3.NC E8I
Cre mice (restricted to
CD8+ T cells only) exhibit enhanced expression of LAG3
on the respective T cell subsets in B16-F10 or MC38
tumors, co-expressing with PD1. Despite increased LAG3
expression, no difference in B16-F10 or MC38 tumor
growth was observed in either LAG3.NC CD4Cre or
LAG3.NC E8ICre mice compared with wild-type litter-
mates. Upon therapeutic administration of anti-PD1 anti-
body (clone G4), MC38 tumor-bearing wild-type mice
show significant tumor regression and 40% become
tumor-free resulting in long-term survival. LAG3.NC
CD4Cre mice were resistant to anti-PD1 therapy and suc-
cumb to tumor growth. However, anti-PD1 mediated
tumor regression and long-term survival in LAG3.NC
E8ICre mice. Analysis of re-stimulated CD8+ TILs isolated
from LAG3.NC CD4Cre mice did not show enhanced
IFN-gamma and TNF-alpha production following anti-
PD1 therapy, which was observed with LAG3.NC E8ICre
mice or wild-type littermates. Moreover, reduced prolif-
eration was observed for all T cell subsets in LAG3.NC
CD4Cre mice compared with LAG3.NC E8ICre and wild-
type littermates following anti-PD1 treatment. As
LAG3.NC CD4Cre, but not LAG3.NC E8ICre mice, are
resistant to the favorable antitumor immune effects
induced by anti-PD1, this suggests that enhanced LAG3
expression on CD4+ T cells or Tregs may act as a barrier
to effective anti-PD1 immunotherapy. LAG3.NC mice
crossed with Cre that restricts non-cleavable LAG3 to
Tregs (Foxp3
yfpiCre) or CD4+ T cells (ThPOKCre) are
currently under analysis.
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